Elena Elkin, PhD

Associate Attending Outcomes Research Scientist
Elena Elkin
Office Phone:
646-888-4472
Education:
Harvard University

Current Research Interests

Dr. Elkin's primary research interest is evaluating determinants of cancer screening, treatment and outcomes using population-based observational data analysis, decision analysis and patient surveys.  Her funded research agenda includes studies of the relationship between the availability of mammography resources and mammography utilization with a focus on geographic and racial disparities in access to and use of mammography; surveys of radiology facilities to assess access to screening mammography and access to low-dose chest CT for lung cancer screening; development and evaluation of a web-based decision aid for women ages 40-49 considering screening mammography; cost-effectiveness analysis of a patient-directed intervention to increase screening mammography in survivors of Hodgkin lymphoma; and studies of treatment patterns, complications, survival and costs in urologic cancers, gastrointestinal cancers and head and neck cancers in the population-based linked SEER-Medicare dataset.  Other research interests include studying the economic impact of cancer treatment on patients, their families and the health care system, and understanding and improving clinical decision-making processes from both patient and provider perspectives.

Publications by Elena Elkin

Elkin EB, Hurria A, Mitra N, Schrag D, Panageas KS. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol, 2006; 24:2757-2764.

Elkin EB, Vickers AJ, Kattan MW. Primer: using decision analysis to improve clinical decision making in urology. Nat Clin Pract Urol. 2006; 3:439-448.

Elkin EB, Hudis C, Begg CB, Schrag DS, The effect of changes in tumor size on breast cancer survival in the U.S., 1975-1999. Cancer, 2005; 104:1149-57.

Elkin EB, Weinstein MC, Kuntz KM, Bunnell CA, Weeks JC. Adjuvant ovarian suppression versus chemotherapy for premenopausal, hormone-responsive breast cancer: quality of life and efficacy tradeoffs. Breast Cancer Res Treat, 2005; 93:25-34.

Elkin EB, Cowen ME, Cahill D, Steffel M, Kattan MW. Preference assessment method affects decision-analytic recommendations: A prostate cancer treatment example. Med Decis Making, 2004;24:504-510.

Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC. HER-2 testing and trastuzumab therapy for metastatic breast cancer: A cost-effectiveness analysis. J Clin Oncol 2004; 22:854-63.

Elkin EB, Kim SHM, Casper ES, Kissane DW, Schrag D. Desire for information and involvement in treatment decisions: elderly cancer patients' preferences and their physicians' perceptions. J Clin Oncol 2007;25:5275-5280.